Financhill
Sell
41

QNTM Quote, Financials, Valuation and Earnings

Last price:
$22.63
Seasonality move :
27.9%
Day range:
$19.11 - $22.50
52-week range:
$2.70 - $38.25
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
13.41x
Volume:
195.4K
Avg. volume:
337.4K
1-year change:
133.48%
Market cap:
$76.9M
Revenue:
--
EPS (TTM):
-$15.23

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
QNTM
Quantum BioPharma
-- -- -- -- --
AUPH
Aurinia Pharmaceuticals
$64.3M $0.14 12.38% 1340% $10.00
EDSA
Edesa Biotech
-- -- -- -- $10.33
LEXX
Lexaria Bioscience
$137K -- 63.1% -- $6.33
MDCX
Medicus Pharma
-- -$0.27 -- -27.42% $19.67
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
QNTM
Quantum BioPharma
$22.46 -- $76.9M -- $0.00 0% --
AUPH
Aurinia Pharmaceuticals
$8.85 $10.00 $1.2B 31.61x $0.00 0% 5.18x
EDSA
Edesa Biotech
$2.26 $10.33 $15.9M -- $0.00 0% 25.98x
LEXX
Lexaria Bioscience
$0.87 $6.33 $17M -- $0.00 0% 24.08x
MDCX
Medicus Pharma
$3.03 $19.67 $48.3M -- $0.00 0% --
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
QNTM
Quantum BioPharma
-- 0.914 -- --
AUPH
Aurinia Pharmaceuticals
-- 0.750 -- 5.16x
EDSA
Edesa Biotech
-- -0.885 -- --
LEXX
Lexaria Bioscience
-- -0.920 -- 3.35x
MDCX
Medicus Pharma
-- -1.452 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
QNTM
Quantum BioPharma
-- -$3.4M -- -- -- -$4.3M
AUPH
Aurinia Pharmaceuticals
$53.9M $23.4M 10.83% 10.83% 40.69% $1.3M
EDSA
Edesa Biotech
-- -$1.6M -- -- -- -$2.4M
LEXX
Lexaria Bioscience
$174K -$3.8M -147.06% -147.06% -2155.41% -$3.6M
MDCX
Medicus Pharma
-- -$5.1M -- -- -- -$3.9M

Quantum BioPharma vs. Competitors

  • Which has Higher Returns QNTM or AUPH?

    Aurinia Pharmaceuticals has a net margin of -- compared to Quantum BioPharma's net margin of 37.37%. Quantum BioPharma's return on equity of -- beat Aurinia Pharmaceuticals's return on equity of 10.83%.

    Company Gross Margin Earnings Per Share Invested Capital
    QNTM
    Quantum BioPharma
    -- -$3.53 --
    AUPH
    Aurinia Pharmaceuticals
    86.27% $0.16 $350.2M
  • What do Analysts Say About QNTM or AUPH?

    Quantum BioPharma has a consensus price target of --, signalling upside risk potential of 2931.08%. On the other hand Aurinia Pharmaceuticals has an analysts' consensus of $10.00 which suggests that it could grow by 12.99%. Given that Quantum BioPharma has higher upside potential than Aurinia Pharmaceuticals, analysts believe Quantum BioPharma is more attractive than Aurinia Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    QNTM
    Quantum BioPharma
    0 0 0
    AUPH
    Aurinia Pharmaceuticals
    3 1 0
  • Is QNTM or AUPH More Risky?

    Quantum BioPharma has a beta of 0.675, which suggesting that the stock is 32.535% less volatile than S&P 500. In comparison Aurinia Pharmaceuticals has a beta of 1.158, suggesting its more volatile than the S&P 500 by 15.808%.

  • Which is a Better Dividend Stock QNTM or AUPH?

    Quantum BioPharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aurinia Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Quantum BioPharma pays -- of its earnings as a dividend. Aurinia Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios QNTM or AUPH?

    Quantum BioPharma quarterly revenues are --, which are smaller than Aurinia Pharmaceuticals quarterly revenues of $62.5M. Quantum BioPharma's net income of -$8.6M is lower than Aurinia Pharmaceuticals's net income of $23.3M. Notably, Quantum BioPharma's price-to-earnings ratio is -- while Aurinia Pharmaceuticals's PE ratio is 31.61x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Quantum BioPharma is -- versus 5.18x for Aurinia Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    QNTM
    Quantum BioPharma
    -- -- -- -$8.6M
    AUPH
    Aurinia Pharmaceuticals
    5.18x 31.61x $62.5M $23.3M
  • Which has Higher Returns QNTM or EDSA?

    Edesa Biotech has a net margin of -- compared to Quantum BioPharma's net margin of --. Quantum BioPharma's return on equity of -- beat Edesa Biotech's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    QNTM
    Quantum BioPharma
    -- -$3.53 --
    EDSA
    Edesa Biotech
    -- -$0.30 --
  • What do Analysts Say About QNTM or EDSA?

    Quantum BioPharma has a consensus price target of --, signalling upside risk potential of 2931.08%. On the other hand Edesa Biotech has an analysts' consensus of $10.33 which suggests that it could grow by 357.23%. Given that Quantum BioPharma has higher upside potential than Edesa Biotech, analysts believe Quantum BioPharma is more attractive than Edesa Biotech.

    Company Buy Ratings Hold Ratings Sell Ratings
    QNTM
    Quantum BioPharma
    0 0 0
    EDSA
    Edesa Biotech
    1 0 0
  • Is QNTM or EDSA More Risky?

    Quantum BioPharma has a beta of 0.675, which suggesting that the stock is 32.535% less volatile than S&P 500. In comparison Edesa Biotech has a beta of 0.393, suggesting its less volatile than the S&P 500 by 60.718%.

  • Which is a Better Dividend Stock QNTM or EDSA?

    Quantum BioPharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edesa Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Quantum BioPharma pays -- of its earnings as a dividend. Edesa Biotech pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios QNTM or EDSA?

    Quantum BioPharma quarterly revenues are --, which are smaller than Edesa Biotech quarterly revenues of --. Quantum BioPharma's net income of -$8.6M is lower than Edesa Biotech's net income of -$1.6M. Notably, Quantum BioPharma's price-to-earnings ratio is -- while Edesa Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Quantum BioPharma is -- versus 25.98x for Edesa Biotech. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    QNTM
    Quantum BioPharma
    -- -- -- -$8.6M
    EDSA
    Edesa Biotech
    25.98x -- -- -$1.6M
  • Which has Higher Returns QNTM or LEXX?

    Lexaria Bioscience has a net margin of -- compared to Quantum BioPharma's net margin of -2177.64%. Quantum BioPharma's return on equity of -- beat Lexaria Bioscience's return on equity of -147.06%.

    Company Gross Margin Earnings Per Share Invested Capital
    QNTM
    Quantum BioPharma
    -- -$3.53 --
    LEXX
    Lexaria Bioscience
    98.52% -$0.21 $5.2M
  • What do Analysts Say About QNTM or LEXX?

    Quantum BioPharma has a consensus price target of --, signalling upside risk potential of 2931.08%. On the other hand Lexaria Bioscience has an analysts' consensus of $6.33 which suggests that it could grow by 627.97%. Given that Quantum BioPharma has higher upside potential than Lexaria Bioscience, analysts believe Quantum BioPharma is more attractive than Lexaria Bioscience.

    Company Buy Ratings Hold Ratings Sell Ratings
    QNTM
    Quantum BioPharma
    0 0 0
    LEXX
    Lexaria Bioscience
    0 0 0
  • Is QNTM or LEXX More Risky?

    Quantum BioPharma has a beta of 0.675, which suggesting that the stock is 32.535% less volatile than S&P 500. In comparison Lexaria Bioscience has a beta of 0.892, suggesting its less volatile than the S&P 500 by 10.756%.

  • Which is a Better Dividend Stock QNTM or LEXX?

    Quantum BioPharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lexaria Bioscience offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Quantum BioPharma pays -- of its earnings as a dividend. Lexaria Bioscience pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios QNTM or LEXX?

    Quantum BioPharma quarterly revenues are --, which are smaller than Lexaria Bioscience quarterly revenues of $174K. Quantum BioPharma's net income of -$8.6M is lower than Lexaria Bioscience's net income of -$3.8M. Notably, Quantum BioPharma's price-to-earnings ratio is -- while Lexaria Bioscience's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Quantum BioPharma is -- versus 24.08x for Lexaria Bioscience. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    QNTM
    Quantum BioPharma
    -- -- -- -$8.6M
    LEXX
    Lexaria Bioscience
    24.08x -- $174K -$3.8M
  • Which has Higher Returns QNTM or MDCX?

    Medicus Pharma has a net margin of -- compared to Quantum BioPharma's net margin of --. Quantum BioPharma's return on equity of -- beat Medicus Pharma's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    QNTM
    Quantum BioPharma
    -- -$3.53 --
    MDCX
    Medicus Pharma
    -- -$0.42 --
  • What do Analysts Say About QNTM or MDCX?

    Quantum BioPharma has a consensus price target of --, signalling upside risk potential of 2931.08%. On the other hand Medicus Pharma has an analysts' consensus of $19.67 which suggests that it could grow by 549.07%. Given that Quantum BioPharma has higher upside potential than Medicus Pharma, analysts believe Quantum BioPharma is more attractive than Medicus Pharma.

    Company Buy Ratings Hold Ratings Sell Ratings
    QNTM
    Quantum BioPharma
    0 0 0
    MDCX
    Medicus Pharma
    2 0 0
  • Is QNTM or MDCX More Risky?

    Quantum BioPharma has a beta of 0.675, which suggesting that the stock is 32.535% less volatile than S&P 500. In comparison Medicus Pharma has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock QNTM or MDCX?

    Quantum BioPharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Medicus Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Quantum BioPharma pays -- of its earnings as a dividend. Medicus Pharma pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios QNTM or MDCX?

    Quantum BioPharma quarterly revenues are --, which are smaller than Medicus Pharma quarterly revenues of --. Quantum BioPharma's net income of -$8.6M is lower than Medicus Pharma's net income of -$5.1M. Notably, Quantum BioPharma's price-to-earnings ratio is -- while Medicus Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Quantum BioPharma is -- versus -- for Medicus Pharma. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    QNTM
    Quantum BioPharma
    -- -- -- -$8.6M
    MDCX
    Medicus Pharma
    -- -- -- -$5.1M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will GoodRX Stock Bounce Back?
Will GoodRX Stock Bounce Back?

GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…

Will FCX Benefit From Tariffs?
Will FCX Benefit From Tariffs?

Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…

Can Levi Stock Double?
Can Levi Stock Double?

Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…

Stock Ideas

Buy
70
Is NVDA Stock a Buy?

Market Cap: $4.2T
P/E Ratio: 58x

Buy
62
Is MSFT Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 43x

Sell
40
Is AAPL Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 35x

Alerts

Buy
82
SBET alert for Jul 17

SharpLink Gaming [SBET] is down 3.83% over the past day.

Buy
89
EXOD alert for Jul 17

Exodus Movement [EXOD] is down 2.15% over the past day.

Buy
60
U alert for Jul 17

Unity Software [U] is up 7.48% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock